Thankfully, I tuned out BEFORE he did that! I would have lost my lunch! What a charlatan! He has no shame, and no dignity! On that note ...
Have a good weekend!
And grandstanding, as usual! "me, me, me"!!! Doing his usual "community organizer in chief" schtick! I had to turn it off! Talk about politicizing a tragedy! But, as his old buddy Rahm always said, "don't let a crisis go to waste"!!
Geez, f2j ... I wouldn't exactly call that "making love"! ;-) Just a girl's perspective! lol
Have a good weekend!
Then why do you find it necessary to compromise someone else's i.d.? One tends to lose a little credibility in that regard!
Yes, I misspoke about "large". I guess I just meant that the % had increased by a fair amount and that may even have explained some of the most recent move to over $13 ... getting a little hug, if you know what I mean? I just meant it was significant enough to keep a little pressure on the upward move from here on til we get any update or news. No worries!
With the large short interest, I don't see any quick snap backs happening, absent of news or upgrades. Like I said yesterday, it really reminds me of the way FOMX traded. Although, they did do a secondary at $9.50 when they were in the $10's and it never even touched the offering level. But, it is still consolidating in the $11's which is what I expect TROV to do ... hey, I guess that's IS double digits, though! '-)
You DO realize that most of the posters here have been in this since around $10 (some lower and some higher),but well south of $20, so there are no worries! I "get a kick out of you" johnny come lately types who show up here after a 200-300% gain has been made!
Was that before Pete's debut on CNBC? It put a floor under us and lots of new eyeballs on the pps, too. Throw in the S&P 600 and, they're in for a slow boil!!
Look at the charts and compare the O/S and float. FOMX ran up near $14 and then pulled back on NO news. Has been consolidating now and bucking the downtrend in biotech. I'm thinking, unless there is a secondary, this may just be the same thing.
Cramer said this a.m. that it would be a non-event, too, and IF the health care stocks sold off because of a negative ruling, it would be "buy time". It's a moot point from here on out! No one has to be "right"!
We "sensed" it at the beginning of the week. If they want to take advantage of these levels to fill the coffers to the brim, so be it! I'm thinking Matt et al know what they're doing!!
I think it might be as easy as we were near our high, along with the overall market and this is the slowest time for biotechs of the year. Or...they're just dumb!! ;-)
Liar? I think not! I was the first to mention here that it "felt" like a secondary might be coming, and I thought it might be in the $9.50 area. You are the one that takes things to extremes and out of context. It is what it is ... if you traded out, good for you. Why don't you show some class and act like "you've been there before"? Karma's a b*tch!
Not saying it CAN'T happen ... God knows the world economy is all smoke and mirrors with monetary policy being what it is. I'm just saying that, just like TROV, the market has been hitting new highs. It should rest and even pull back. 5-7% would not be a tragedy, nor unusual or unexpected, imo.
silver, et al
I realize AKAO's schedule got set back, and that, obviously CEMP and TTPH are further along, but do they warrant a market cap 15 & 16 times higher than AKAO'S?
He's a "value" investor, and I suspect he doesn't see any value in the market at these levels. However, there are over-valued stocks, as well as some that are still under-valued. Now that he's out of NFLX, he was predicting gloom and doom for them all the while talking his book with his huge AAPL investment. He's no more of an expert than some other hedgies. When Greece hiccupped today, and then he chimed in, the computers started the indiscriminate selling. As long as interest rates remain low, the market will be fine. And I don't really think the economy can sustain more than a half point combined increase in the next year. GDP was revised down, I think, even though unemployment remains low. Keep some cash ... and we'll be fine. If you think TROV is over-valued at $200M mc, then I would sell.
Hey ... I haven't been around much this week. Here is the answer to your question about OSIR. No longer an issue ... in fact, turned into a positive with shares in Mesoblast.
By Scott Dance, The Baltimore Sun
This article is related to: Medical Research,
Diseases and Illnesses,
October 11, 2013, 8:05 PM
Columbia biotechnology company Osiris Therapeutics has reached a deal to sell its marquee stem-cell drug, the first to win government approval, for up to $100 million..
Lab-grown blood vessels made with less adoMaryland HealthLab-grown blood vessels made with less adoSee all relatedí
A subsidiary of Australian company Mesoblast Ltd. has agreed to pay $50 million for the technology behind Prochymal and the drug itself, and Osiris could receive up to $50 million more if the drug passes clinical trials and regulatory reviews, the companies said.
z Got something to say? Start the conversation and be the first to comment.
Add a commentí
Prochymal is being evaluated in a final round of clinical trials for use in treating Crohn's disease as well as a disorder known as graft-versus-host disease, which can occur after stem cell or bone marrow transplants. Osiris was founded in 1992 to develop stem-cell therapies that can be used to stop inflammation and regenerate tissue.
The deal would mean Osiris moving on from what has been its key project for more than 20 years. Company officials said the sale allows them to focus on other projects with potential.
"With this transaction, we will focus our business on those areas that are of greatest commercial value to Osiris moving forward," Osiris Chairman Peter Friedli said in a statement.
Other projects the company is working on include Chondrogen and Osteocel-XC, both drugs that stimulate bone regeneration.
Company officials were not available for comment Friday.
Osiris broke ground in the global stem-cell research field in May 2012 when it announced it had received the world's first governmental approval to market a stem-cell drug. Canada granted the first approval, and New Zealand soon followed.
" I had a crazy dream last night that CEMP and TTPH merged then bought AKAO. Then I woke up all mad."
I like it!! I'm accumulating AKAO at the $6-ish level. We've all seen how these things eventually play out!
Today is just "noise" ...